Recent research indicated Annexin 2 contributes to chemo-resistance and cancer progression in non-small-cell lung cancer and estrogen-receptor negative breast cancer [10,11], and there are drug development research studies about targeting Annexin 2 [12]. The gene discussed is ANXA2; the disease is estrogen-receptor negative breast cancer.